Novo Nordisk announced a strategic partnership with OpenAI that will place Novo Nordisk at the forefront of AI transformation in healthcare and help the company bring new and better treatment options to patients faster. The partnership will apply advanced AI capabilities to analyse complex datasets, identify promising drug candidates, and reduce the time required to move from research to patient. It has been structured with strict data protection, governance and human oversight to ensure ethical and compliant use.
Novo Nordisk will integrate OpenAI's most advanced AI capabilities globally from drug discovery to commercial operations, empowering talent to move faster, work smarter, and deliver life-changing outcomes for patients. Pilot programmes will launch across research & development, manufacturing and commercial operations, with full integration by the end of 2026. The partnership will also apply OpenAI?s capabilities to improve efficiency in manufacturing, supply chain and distribution and corporate operations.
